Biotia

For too long, UTI diagnosis has relied on a symptom checklist, urinalysis, and a standard urine culture. This method has real limitations, especially for recurrent and complicated UTI patients. But things are changing. Clinical metagenomic-based diagnostic testing is empowering patients and providers with more comprehensive microbial information, and the evidence for its use is growing. A recent study Biotia completed in collaboration with Bumrungrad Hospital in Bangkok, Thailand, now published in the journal Frontiers in Cellular and Infection Microbiology, compared our clinical metagenomic assay to standard urine culture. Among 358 urine samples tested, 231 were deemed positive, and 137 were deemed negative by standard urine culture. When the culture-negative urine samples were tested with our method, we found microbial DNA in 71.6% (n=98) of samples. Negative urine culture ≠ nothing is there. You may just need a better test. Read the full study here: https://lnkd.in/eF_GEDYX #Biotia #UTI #infectiousdiseases #diagnostics #medicaldevices #obgyn #urology #womenshealth #publichealth

Biotia is Bay Area-bound! Next week, Biotia's Co-Founders Dr. Niamh B. O'Hara and Dr. Christopher Mason will be attending JPMorgan Healthcare Conference 2026. Come find us to chat about next-generation sequencing, artificial intelligence, and infectious diseases! 🦠 🧬

We are excited to share that we have received New York State CLIA/CLEP approval for our Antimicrobial Resistance addendum to the BIOTIA-ID Urine NGS Assay! This approval allows us to report the detection of antibiotic resistance genes (ARGs) for several different classes of antibiotics to both clinicians and patients. This reporting helps clinicians select antimicrobial therapy for patients with recurrent and complicated urinary tract infections, improving both AMR stewardship and patient outcomes. While numerous tests on the market purport to reliably detect resistance genes, few have reached this level of clinical and regulatory rigor, positioning the BIOTIA-ID Urine NGS assay as a frontrunner in UTI diagnostics. Stay tuned for future feature developments–more to come soon! #Biotia #UTIs #Diagnostics #InfectiousDiseases

Come find us at ID Week 2025 🦠 ! Our Director of Business Development, Lorenzo Uccellini, PhD, will be presenting a poster tomorrow Wednesday October 22nd. Our poster highlights some of the hard work our team has put into improving AMR prediction approaches, specifically for Klebsiella pneumoniae. Details below ⬇️ Title: A dual-mechanism model incorporating efflux pumps and resistance genes to predict multi-drug resistance in Klebsiella pneumoniae Type: Poster- Diagnostics: Typing/sequencing Time: 12:15 PM - 1:30 PM ET #IDWeek2025 #IDWeek #IDSA #SHEA #PIDS #AMR #clinicalmetagenomics

Our CEO, Niamh B. O'Hara, joined Everywhere Ventures' podcast for a conversation with Cristian Ponce to discuss how we are fighting infectious diseases by leveraging pathogen genomics and artificial intelligence. Tune in on your favorite podcast channels below!

The BIOTIA-ID Urine Test is revolutionizing the way we test and treat recurrent, complicated, and culture-negative urinary tract infections. Our latest white paper discusses the benefits of using clinical metagenomic approaches for diagnosing UTIs and summarizes some key clinical evidence supporting the BIOTIA-ID Urine Test's use. Some highlights: 💡 Urine culture has limitations that lead to unnecessary diagnostic uncertainty. 💡 The BIOTIA-ID Urine Test is backed by comprehensive analytical and clinical validation – demonstrating its ability to outperform urine culture. 💡 With patient management guidelines, in addition to wet lab and bioinformatic optimizations, clinical metagenomic tests can overcome common concerns, such as overdiagnosis. Read the paper for a deep dive, and make sure to share if you learned something new! #Biotia #clinicalmetagenomics #infectiousdiseasediagnostics #UTI #urology #obgyn #clinicalguidelines #diagnosticstewardship #amr

NEW PUBLICATION ALERT 📝 ! A perspective piece from the Biotia team and key research collaborators from New York, Rio de Janeiro, Hamburg, and Barcelona has now been published in Cell Reports Sustainability. The article, entitled "The challenges and opportunities in creating a One Health warning system for pandemics," reflects on the lessons learned from implementing our GeoSeeq platform for outbreak detection and pandemic preparedness in response to dengue virus 🦟 in Brazil. "Pandemics remain a significant global health risk – multimodal tracking that includes both climatological and molecular surveillance data can reduce the risk of major outbreaks and improve health outcomes at the local level," said Dr. David Danko, Chief Technical Officer. You can read the whole piece at Cell Reports Sustainability's website. Link in the comments. Advanced Science Research Center, GC/CUNY | State University of New York Downstate Health Sciences University | Weill Cornell Medicine | Fundação Oswaldo Cruz (Fiocruz) | Bernhard Nocht Institute for Tropical Medicine | Barcelona Institute for Global Health (ISGlobal) | Heimdall Bio #Biotia #infectiousdiseases #pandemicpreparedness #pathogengenomics #artificialintelligence #publichealth #globalhealth #onehealth #surveillance #climatechange #vectorbornedisease

🔬 Advancing Precision Diagnostics in UTI Care DigitalDx Ventures portfolio company Biotia is partnering with Live UTI Free, a leading patient advocacy organization, to drive patient engagement and awareness around our Test-to-Treat initiative, powered by the BIOTIA-ID Urine Test. This collaboration highlights a growing need for innovative, data-driven solutions in the $8B+ UTI diagnostics and treatment market. By combining cutting-edge genomics with patient education, we’re enabling smarter, faster, and more personalized care pathways for recurrent UTI patients. A new article from Live UTI Free outlines how this initiative empowers patients and unlocks a more scalable, outcomes-focused approach to infectious disease diagnostics. Congratulations to Niamh B. O'Hara, Christopher Mason, Dorottya Nagy-Szakal MD PhD and the Biotia Team! READ: https://lnkd.in/eZUDW-BJ 📈 Transforming care. Empowering patients. Building the future of precision health. #HealthTech #InfectiousDisease #DigitalHealth #PrecisionMedicine #WomensHealth #VentureCapital #Biotia #PatientEngagement #HealthcareInnovation #Diagnostics Michele Colucci, Esq. Erin Niehaus - CFP®, CEPA

A new UTI test and telehealth service has been recently launched by Biotia  and is now available in the US. The new test, BIOTIA-ID Urine, is for UTI patients who meet one of these criteria:  👉 Have been suffering from recurrent or chronic UTIs (two or more UTIs within 6 months, or three or more UTIs within 12 months) 👉 Have an underlying condition that increases the risk of UTI complications, such as diabetes, cancer, kidney disease, or other conditions 👉 Recently received negative test results using other UTI tests, but still have UTI symptoms BIOTIA-ID Urine was designed to address the limitations of the current standard of care: the urine culture. Standard urine culture has poor sensitivity and misses identification of many pathogens that don’t grow well in culture - for example, slow growing pathogens, or pathogens that require specific conditions to grow.  BIOTIA-ID Urine is more sensitive and specific and can identify pathogens that standard culture can’t, including those that may be linked to recurrent or chronic UTIs. Read more on our website about Biotia-ID Urine, how to order, and how their telehealth service can support the process: